CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Capi, Matilde, De Angelis, Valerio, De Bernardini, Donatella, De Luca, Ottavia, Cipolla, Fabiola, Lionetto, Luana, Simmaco, Maurizio, Martelletti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038117/
https://www.ncbi.nlm.nih.gov/pubmed/33916043
http://dx.doi.org/10.3390/jcm10071429
_version_ 1783677301216509952
author Capi, Matilde
De Angelis, Valerio
De Bernardini, Donatella
De Luca, Ottavia
Cipolla, Fabiola
Lionetto, Luana
Simmaco, Maurizio
Martelletti, Paolo
author_facet Capi, Matilde
De Angelis, Valerio
De Bernardini, Donatella
De Luca, Ottavia
Cipolla, Fabiola
Lionetto, Luana
Simmaco, Maurizio
Martelletti, Paolo
author_sort Capi, Matilde
collection PubMed
description Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor (“gepants”) and of a new class of medications called “Ditans”. This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.
format Online
Article
Text
id pubmed-8038117
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80381172021-04-12 CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine Capi, Matilde De Angelis, Valerio De Bernardini, Donatella De Luca, Ottavia Cipolla, Fabiola Lionetto, Luana Simmaco, Maurizio Martelletti, Paolo J Clin Med Review Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor (“gepants”) and of a new class of medications called “Ditans”. This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy. MDPI 2021-04-01 /pmc/articles/PMC8038117/ /pubmed/33916043 http://dx.doi.org/10.3390/jcm10071429 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Capi, Matilde
De Angelis, Valerio
De Bernardini, Donatella
De Luca, Ottavia
Cipolla, Fabiola
Lionetto, Luana
Simmaco, Maurizio
Martelletti, Paolo
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title_full CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title_fullStr CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title_full_unstemmed CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title_short CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
title_sort cgrp receptor antagonists and 5-ht1f receptor agonist in the treatment of migraine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038117/
https://www.ncbi.nlm.nih.gov/pubmed/33916043
http://dx.doi.org/10.3390/jcm10071429
work_keys_str_mv AT capimatilde cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT deangelisvalerio cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT debernardinidonatella cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT delucaottavia cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT cipollafabiola cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT lionettoluana cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT simmacomaurizio cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine
AT martellettipaolo cgrpreceptorantagonistsand5ht1freceptoragonistinthetreatmentofmigraine

Ejemplares similares